Vifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this time in high-risk kidney transplant patients. A phase 3 trial of ANG-3777 ...
Vifor Pharma has pledged to pay £23 million to the NHS after Britain’s competition watchdog raised concerns the drugs firm had been making misleading claims about the safety of a rival’s iron ...
Cara and Vifor are meanwhile planning a new phase 3 trial of oral difelikefalin in pre-dialysis CKD patients, which could expand the market for the drug significantly.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback